Xedev
Private Company
Total funding raised: $2.5M
Overview
Xedev is a Belgian CDMO founded in 2016, providing end-to-end drug product development and manufacturing services for small molecules, peptides, and biologics. The company differentiates itself through a flexible, client-centric approach, offering small-scale precision testing and scalable processes to de-risk development. Its core expertise lies in enabling technologies like amorphous solid dispersions and spray drying to improve solubility and bioavailability, serving clients from preclinical stages through Phase II clinical trials.
Technology Platform
Specialized in formulation and process development for solid dosage forms, with advanced expertise in enabling technologies like amorphous solid dispersions, spray drying, hot melt extrusion, and spray congealing to improve solubility, bioavailability, and stability of challenging molecules (small molecules, peptides, biologics).
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Xedev competes in a crowded CDMO market against large multinational firms (e.g., Lonza, Catalent) and numerous specialized peers. Its differentiation is based on a flexible, client-centric approach, deep expertise in advanced solid dosage formulations (especially for solubility enhancement), and a focus on the preclinical-to-Phase II segment, offering agility and scientific collaboration that larger players may not provide.